Released on: March 20, 2008, 11:30 am

Press Release Author: GTCbio

Industry: Biotech

Press Release Summary: Dr. Didier Leroy, Team Leader of Lead Discovery Technologies,
Geneva Research Center at Merck-Serono will be presenting at GTCbio's 3rd Protein
Kinase in Drug Discovery Conference.



Press Release Body: Dr. Didier Leroy, Team Leader of Lead Discovery Technologies,
Geneva Research Center at Merck-Serono will be presenting at GTCbio's 3rd Protein
Kinase in Drug Discovery Conference on May 4-5, 2008 in San Diego, CA.

As the Team Leader at Merck-Serono, Dr. Leroy's goal in oncology is to develop novel
therapies that specifically target cancer cells and are more tolerable for patients.
His research is focused on all aspects of disease pharmacology with the ultimate
goal to increase patient survival and improve quality of life. In the Neurological,
Autoimmune and Inflammatory disease areas, Dr. Leroy focuses on all aspects of
disease biology and pharmacology research with the goal to identify novel therapies
that provide symptomatic relief and slow or stop disease progression.

At the conference, Dr. Leroy will discuss the evolution of the major strategies and
technologies that allowed the identification of kinase inhibitors with a potential
use in oncology, neurology, inflammation and infectious diseases. The
characteristics of compounds identified by molecular and cellular-based assays using
radioactive, fluorescent and label free approaches will be revealed. Dr. Leroy will
also discuss the progression of key molecules within the drug discovery pipeline
following the early determination of DMPK/Tox parameters and molecular modes of
action as well as the novelty and quality of newly identified kinase inhibitors
according to the complexity of the technologies used from primary screening to Lead
optimization steps.

GTCbio's 3rd Protein Kinase in Drug Discovery Conference on May 5-6, 2008 in San
Diego, CA will also cover Kinase Drug Design, Kinase Targets and Inhibitors in CNS
Disorders, Oncology, and Inflammatory Disorders, as well as New Technologies in
Screening and Identification of Targets and Inhibitors.

The conference also features presentations from other leading organizations such as
Johnson & Johnson, Roche, Pfizer, Merck, GlaxoSmithKline, Salk Institute,
AstraZeneca, Methylgene, UCSD, and many more. The full agenda is available online at
www.gtcbio.com.


For more information including a detailed agenda, exhibitor opportunities and
registration information visit http://gtcbio.com/userAgenda.aspx?id=121.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical
industries. Our goal is to facilitate the exchange of biopharmaceutical and
biomedical intelligence between industry leaders, academic and government
organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company
founded in 2002.


Web Site: http://

Contact Details: GTCBIO
434 W Foothill Blvd. Monrovia, CA. 91016
direc(626) 256-6405, fax(626) 256-6460
infogtcbio@gtcbio.com